Sun Pharma’s psoriasis drug

New Delhi: Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug Ilumya in India for the treatment of moderate-to-severe plaque psoriasis. A novel biologic treatment, Ilumya (Tildrakizumab) has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis. Already available in 35 countries, Ilumya has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years, a statement said.